JIMMY D MORGAN

Allopathic & Osteopathic Physicians|Emergency Medicine JOPLIN, MO NPI 1477560712

General Payments — all program years on this page

$358,172.90

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 153
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $75,200.00 across 28 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $75,200.0028

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Takeda Pharmaceuticals U.S.A., Inc. $61,200.0024
Fresenius Kabi USA, LLC $14,000.004

By program year

Program yearAmountRecords
2018 $24,894.4616
2019 $46,628.4422
2020 $54,050.0023
2021 $58,100.0024
2022 $58,800.0024
2023 $40,500.0016
2024 $75,200.0028

Records — PY2024 (28)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1137638304 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638306 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 01/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638308 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638310 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 02/14/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638312 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638314 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 03/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638316 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638318 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 04/17/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638320 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638322 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 05/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638324 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638326 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 06/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638328 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638330 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 07/12/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638332 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638334 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 08/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638336 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638338 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 09/11/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638340 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638342 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 10/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638344 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638346 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 11/13/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638348 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1137638350 Takeda Pharmaceuticals U.S.A., Inc. $2,550.00 12/09/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1146959318 Fresenius Kabi USA, LLC $3,200.00 05/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1146959320 Fresenius Kabi USA, LLC $3,200.00 05/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1146959322 Fresenius Kabi USA, LLC $3,600.00 05/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1146959324 Fresenius Kabi USA, LLC $4,000.00 05/08/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.